UNSPSC 51361810: Metomidate hydrochloride

This classification denotes a sedative and hypnotic with the molecular formula C13H14N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SKV88232PJ, chemically known as methyl 1-(.alpha.-methylbenzyl)imidazole-5-carboxylate hydrochloride, but more generally known as metomidate hydrochloride, which bears US NIH Compound Identifier 21474. European Medicines Agency schedules metomidate hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08907MIG.

Most nations, for tariff purposes, schedule metomidate hydrochloride under HS 29332990. SMILES: CC(C1CCCCC1)N2CNCC2C(=O)OC.CL.

UNSPSC 51361810 Metomidate hydrochloride is a Commodity code that nominally refers to a specific pharmaceutical anesthetic agent, but recent state and local procurement activity under this code shows a significant mismatch: the single recent opportunity on file is Seminole County, Florida's IFB for naloxone and drug deactivation systems, neither of which relates to metomidate hydrochloride. The opportunity requests 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. Vendors must submit bids electronically through the county's e-Procurement Portal, include all shipping and delivery costs in their proposal, and comply with drug-free workplace certification, E-Verify requirements, and specific insurance coverages including workers' compensation, commercial general liability, and professional liability. The contract carries a two-year initial term with a one-year renewal option, a three-month probationary period, and potential FEMA funding with associated federal compliance requirements. The code shows little relevant recent activity aligned with its pharmaceutical scope.

Seminole County, Florida represents the only recent issuing body in the available record. The IFB posted June 30, 2026, with a response deadline of July 26, 2023—a date inconsistency in the source suggesting possible data quality issues. Given the mismatch between the code's nominal pharmaceutical content and the actual opportunity being solicited, this code warrants close review before pursuit; the single opportunity does not reflect typical metomidate procurement patterns and may indicate either a tagging error or a shift in how the jurisdiction categorizes public health supply purchases.